Publications, Pharmaceutical

Physiologically-based Pharmacokinetic Models (PBPK) for OINDPs

Physiologically-based Pharmacokinetic Models (PBPK) offer considerable potential to accelerate the development of orally inhaled and nasal drug products (OINDPs), and our ability to construct them is evolving fast.

This Q&A offers an introduction to PBPK models, examining barriers to implementation and progress to date.

The unique value of PBPK models for OINDPs is discussed and transferability, from species to species and between product types is explained. The need for and benefits of a more standardized approach and off-the-shelf software are highlighted. Going forward the expectation is that PBPK models will play an increasingly important role in both OINDP development and associated regulatory submissions. This Q&A provides a perfect introduction for those looking to learn more from pioneers in the field.

Download the OINDPs Q&A
Author(s): Will Ganley
21 Oct 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More About nasal drug delivery expertise

Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery

Find Out More About pulmonary drug delivery expertise

Request Access


Requesting access to Physiologically-based Pharmacokinetic Models (PBPK) for OINDPs.

  • This field is for validation purposes and should be left unchanged.
Back To Top